The C12orf43 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. In this product, the C12orf43 gene has been targeted for disruption using CRISPR/Cas9, yielding a heterogeneous mixture of cells with variable indel profiles at the target locus. This polyclonal format provides a robust loss-of-function system that avoids the biases of single-cell cloning, offering a population-averaged view of gene function. The edited cells are supplied as a ready-to-use pool, facilitating immediate functional assays without the need for further clonal isolation.
The A-549 cell line, established from the alveolar basal epithelium of a 58-year-old male NSCLC patient, is a quintessential model for lung adenocarcinoma research. These adherent epithelial cells harbor clinically relevant mutations, including KRAS G12S and TP53, and have been instrumental in elucidating mechanisms of tumorigenesis and therapeutic resistance. Their robust growth characteristics and compatibility with standard molecular biology techniques make them a preferred host for gene-editing studies.
C12orf43 remains an uncharacterized open reading frame with no validated upstream regulators, downstream effectors, or interacting proteins. Its molecular function is currently undefined, and it has not been assigned to any canonical signaling cascade. However, context-dependent hints suggest possible involvement in cell proliferation, survival, and epithelial?Cmesenchymal transition. The complete absence of functional annotation makes the C12orf43 knockout model a powerful starting point for discovery biology aimed at uncovering new regulatory nodes.
Given the clinical relevance of A-549 cells as a model for lung adenocarcinoma, C12orf43 knockout in this background enables direct investigation of the gene??s role in tumor cell growth, survival, and invasive capacity. The polyclonal editing ensures that functional outcomes reflect the average behavior of the edited population, minimizing clonal outliers. This model is well-suited for unbiased screens to uncover vulnerabilities associated with poorly annotated genes in NSCLC. Furthermore, the epithelial origin of A-549 cells supports studies of EMT-linked processes, a key determinant of metastatic dissemination.
Key applications include cell viability and colony formation assays to measure proliferative and clonogenic potential, transwell migration and invasion assays to assess metastatic behavior, and western blotting and RT-qPCR for protein and mRNA expression analysis. These cells can be employed in synthetic lethality screens, three-dimensional culture models, and target validation studies in drug discovery pipelines. The C12orf43 Knockout A-549 Polyclonal Cells serve as a flexible platform for both academic and industrial researchers focused on decoding the functions of orphan genes in lung adenocarcinoma. For further information, please contact Ascent Research.
